|
|
|
1-10 employees
View all
|
|
Pharmaceuticals
|
|
Baltimore, Maryland, US
|
|
MyMD is a clinical stage biotech pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms.
MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immunometabolic system to control tumor necrosis factor alpha (TNF-α) and other pro-inflammatory cytokines. MYMD-1 is being developed to treat autoimmune diseases, including those currently treated with non-selective TNF-α blocking drugs, and aging and longevity.
Supera-CBD is a drug platform based on a novel (patent pending) synthetic derivative of cannabidiol (CBD) that targets numerous key receptors including CB2 and opioid receptors and inhibits monoamine oxidase. Supera-CBD is being developed to address the rapidly growing CBD market that includes FDA approved drugs and CBD products not currently regulated as a drug.
|
MyMD Pharmaceuticals Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used MyMD Pharmaceuticals email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact MyMD Pharmaceuticals customer service number in your country click here to find.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.